编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding Accelerated for Specific ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

The competitive dynamics in the CML space continue to evolve, with analysts suggesting ELVN-001’s complementary mechanism of action could position it well as a follow-on treatment in second-line or ...

Ascentage Pharma Group International Unsponsored ADR ( ($AAPG) ) has issued an update. On December 8, 2025, Ascentage Pharma presented updated ...

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...